Stock GE9 GENMAB A/S
Add to a list
To use this feature you must be a member
Log inSign up

Financials Genmab A/S BOERSE MUENCHEN

Equities

GE9

DK0010272202

Biotechnology & Medical Research

Real-time BOERSE MUENCHEN
Other stock markets
 10:43:23 2024-06-03 am EDT 		5-day change 1st Jan Change
262 EUR +0.77% Intraday chart for Genmab A/S -0.04% -9.88%
04:19pm Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study MT
06:46am Genmab Announces Initial Data from Phase 2 Cancer Treatment Trial MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 96,408 161,105 172,063 192,229 140,770 124,901 - -
Enterprise Value (EV) 1 85,618 145,026 152,725 169,905 112,635 98,999 92,551 86,034
P/E ratio 43.5 x 34.1 x 57.8 x 35.2 x 32.6 x 28.6 x 20.3 x 15.8 x
Yield - - - - - - - -
Capitalization / Revenue 18 x 15.9 x 20.3 x 13.2 x 8.54 x 6.31 x 5.29 x 4.41 x
EV / Revenue 16 x 14.3 x 18 x 11.6 x 6.84 x 5 x 3.92 x 3.04 x
EV / EBITDA 30.8 x 22.1 x 46.8 x 25.3 x 20.1 x 15.6 x 11 x 7.88 x
EV / FCF 68.7 x 23.7 x 77.3 x 47.3 x 16.1 x 40 x 15.5 x 9.96 x
FCF Yield 1.46% 4.22% 1.29% 2.12% 6.23% 2.5% 6.44% 10%
Price to Book 6.85 x 8.5 x 7.82 x 7.07 x 4.5 x 3.62 x 2.94 x 2.47 x
Nbr of stocks (in thousands) 65,075 65,410 65,423 65,362 65,322 64,482 - -
Reference price 2 1,482 2,463 2,630 2,941 2,155 1,937 1,937 1,937
Announcement Date 2/19/20 2/23/21 2/16/22 2/22/23 2/14/24 - - -
1DKK in Million2DKK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 5,366 10,111 8,482 14,595 16,474 19,796 23,616 28,302
EBITDA 1 2,777 6,572 3,266 6,719 5,616 6,346 8,420 10,925
EBIT 1 2,638 6,313 3,018 6,357 5,321 5,359 7,920 10,555
Operating Margin 49.16% 62.44% 35.58% 43.56% 32.3% 27.07% 33.54% 37.3%
Earnings before Tax (EBT) 1 2,859 5,904 3,983 7,035 5,637 5,874 8,404 10,862
Net income 1 2,166 4,758 3,008 5,522 4,352 4,680 6,612 8,319
Net margin 40.37% 47.06% 35.46% 37.83% 26.42% 23.64% 28% 29.4%
EPS 2 34.03 72.21 45.54 83.65 66.02 67.82 95.34 122.5
Free Cash Flow 1 1,247 6,126 1,976 3,595 7,014 2,478 5,965 8,638
FCF margin 23.24% 60.59% 23.3% 24.63% 42.58% 12.52% 25.26% 30.52%
FCF Conversion (EBITDA) 44.9% 93.21% 60.5% 53.5% 124.89% 39.05% 70.84% 79.07%
FCF Conversion (Net income) 57.57% 128.75% 65.69% 65.1% 161.17% 52.94% 90.22% 103.83%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/19/20 2/23/21 2/16/22 2/22/23 2/14/24 - - -
1DKK in Million2DKK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 S1 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4 2025 Q1
Net sales 1 6,343 3,553 2,310 2,619 2,119 3,162 5,281 4,087 5,227 2,854 4,198 7,052 4,744 4,678 4,143 4,991 9,039 5,284 5,582 4,835
EBITDA 1 4,583 1,345 905 1,016 529 1,263 1,792 1,953 2,974 458 1,520 1,978 1,739 1,899 823 1,511 2,412 1,711 2,070 2,850
EBIT 1 4,568 1,319 890 809 514 1,247 1,761 1,931 2,665 437 1,497 1,934 1,717 1,670 801 391 2,229 1,631 1,827 919
Operating Margin 72.02% 37.12% 38.53% 30.89% 24.26% 39.44% 33.35% 47.25% 50.99% 15.31% 35.66% 27.42% 36.19% 35.7% 19.33% 7.83% 24.66% 30.87% 32.74% 19.01%
Earnings before Tax (EBT) 1 4,682 1,846 1,171 966 612 2,489 3,101 3,272 662 286 1,723 2,009 2,702 926 1,716 185.2 3,374 1,698 1,733 571
Net income 1 3,647 1,402 890 716 465 1,891 2,356 2,582 584 226 1,357 1,583 2,129 640 1,325 455.7 2,598 1,363 1,355 456.8
Net margin 57.5% 39.46% 38.53% 27.34% 21.94% 59.8% 44.61% 63.18% 11.17% 7.92% 32.32% 22.45% 44.88% 13.68% 31.98% 9.13% 28.74% 25.79% 24.28% 9.45%
EPS 2 55.52 21.25 13.47 10.82 7.050 28.66 35.71 39.17 8.820 3.430 20.61 24.03 32.32 9.670 20.18 -5.325 39.51 20.11 19.02 5.810
Dividend per Share 2 - - - - - - - - - - - - - - - - - - - -
Announcement Date 8/12/20 8/11/21 11/10/21 2/16/22 5/11/22 8/10/22 8/10/22 11/9/22 2/22/23 5/10/23 8/3/23 8/3/23 11/7/23 2/14/24 5/2/24 - - - - -
1DKK in Million2DKK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 10,790 16,079 19,338 22,324 28,135 25,902 32,350 38,867
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 1,247 6,126 1,976 3,595 7,014 2,478 5,965 8,638
ROE (net income / shareholders' equity) 19.6% 28.7% 14.6% 22.2% 14.8% 15.6% 16.5% 17.8%
ROA (Net income/ Total Assets) 18.4% 26.2% 13.1% 20.1% 13.3% 13.8% 13.9% 16.1%
Assets 1 11,803 18,143 22,885 27,453 32,704 33,830 47,455 51,570
Book Value Per Share 2 216.0 290.0 336.0 416.0 479.0 535.0 660.0 784.0
Cash Flow per Share 2 21.50 97.60 33.70 59.30 112.0 95.20 126.0 163.0
Capex 1 79 307 252 317 366 501 515 647
Capex / Sales 1.47% 3.04% 2.97% 2.17% 2.22% 2.53% 2.18% 2.29%
Announcement Date 2/19/20 2/23/21 2/16/22 2/22/23 2/14/24 - - -
1DKK in Million2DKK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Genmab A/S

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,937 DKK
Average target price
2,464 DKK
Spread / Average Target
+27.21%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+14.73% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+13.63% 106B
BIONTECH SE Stock BioNTech SE
-2.26% 24.28B
ARGENX SE Stock argenx SE
+0.52% 21.96B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.28% 16.37B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.33% 15.56B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.34% 13.63B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+29.65% 12.27B
INSMED INCORPORATED Stock Insmed Incorporated
+85.12% 8.87B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. GMAB Stock
  4. GE9 Stock
  5. Financials Genmab A/S